It isn't difficult to figure out that the market is impressed with Eli Lilly's (NYSE: LLY) prospects. The company has been one of the best-performing biotech giants in the past year, with its shares up by 34% over the trailing-12-month period.
Market sentiments can be wrong, though, so before rushing to press the buy button, it's essential to dig deeper than Eli Lilly's recent stock performance. Is the company's bull case stronger than the bear one? Let's find out.
Eli Lilly is a longtime leader in the diabetes-care market. The company's current portfolio includes several important medicines in this area. One is Trulicity, which helps control blood-sugar levels in type 2 diabetes patients.
Source Fool.com